ITP (immune thrombocytopenia) is an autoimmune disorder where the body attacks its own blood platelets. This leads to a decrease in the number of platelets and consequently can cause a number of ...

Immune thrombocytopenia (ITP) is a chronic autoimmune disorder associated with platelet destruction and increased bleeding risk, substantial economic burden, and impairment of health-related quality ...

The most pressing questions in ITP involve finding a cure and developing treatments safe for use during pregnancy. I think the major challenges in ITP are several. One, and I think the [rilzabrutinib] ...

Basel, June 15, 2018 - Many patients with the rare blood disorder immune thrombocytopenia (ITP) find the disease has a negative impact on their everyday quality of life, according to interim results ...

Tune in to a powerful episode of the AscellaHealth Podcast Pulse, released in recognition of Rare Disease Awareness Month. Hosted by Gabriella Patone of AscellaHealth, this special edition features an ...

ORLANDO, Fla.—Novartis is divulging details from ianalumab’s summertime phase 3 win in a rare autoimmune blood disorder, and the data suggest the treatment could delay the progression of patients to ...

Please provide your email address to receive an email when new articles are posted on . Patients with immune thrombocytopenia achieved durable platelet count expansion with rilzabrutinib.

ORLANDO -- Adding four monthly infusions of novel ianalumab helped adults with primary immune thrombocytopenia (ITP) achieve durable disease control in the second-line setting while stopping daily ...

Children with newly diagnosed immune thrombocytopenia (ITP) treated with eltrombopag as a frontline therapy show significantly improved platelet responses and other outcomes compared with the standard ...

EAST HANOVER, N.J., Oct. 18, 2017 /PRNewswire/ -- Novartis today announced long-term study results supporting the positive safety and efficacy of Promacta (eltrombopag) in adults with ...